Recently, another CTLA-4 antagonist, tremelimumab, received priority review in the US FDA, supporting the combination of anti-CTLA4 antibody, tremelimumab, and the anti-PDL-1 antibody durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.